BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 25228233)

  • 1. Acellular vaccines for preventing whooping cough in children.
    Zhang L; Prietsch SO; Axelsson I; Halperin SA
    Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD001478. PubMed ID: 25228233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acellular vaccines for preventing whooping cough in children.
    Zhang L; Prietsch SO; Axelsson I; Halperin SA
    Cochrane Database Syst Rev; 2012 Mar; (3):CD001478. PubMed ID: 22419280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acellular vaccines for preventing whooping cough in children.
    Zhang L; Prietsch SO; Axelsson I; Halperin SA
    Cochrane Database Syst Rev; 2011 Jan; (1):CD001478. PubMed ID: 21249646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WITHDRAWN: Acellular vaccines for preventing whooping cough in children.
    Tinnion O; Hanlon M
    Cochrane Database Syst Rev; 2008 Apr; (2):CD001478. PubMed ID: 18425874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WITHDRAWN: Acellular vaccines for preventing whooping cough in children.
    Tinnion ON; Hanlon M
    Cochrane Database Syst Rev; 2007 Jul; (3):CD001478. PubMed ID: 17636677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acellular vaccines for preventing whooping cough in children.
    Tinnion ON; Hanlon M
    Cochrane Database Syst Rev; 2000; (2):CD001478. PubMed ID: 10796648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience.
    Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A;
    Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines.
    Olin P; Rasmussen F; Gustafsson L; Hallander HO; Heijbel H
    Lancet; 1997 Nov; 350(9091):1569-77. PubMed ID: 9393335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diphtheria-tetanus-acellular pertussis vaccine adsorbed (Triacelluvax; DTaP3-CB): a review of its use in the prevention of Bordetella pertussis infection.
    Matheson AJ; Goa KL
    Paediatr Drugs; 2000; 2(2):139-59. PubMed ID: 10937466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB).
    Bar-On ES; Goldberg E; Hellmann S; Leibovici L
    Cochrane Database Syst Rev; 2012 Apr; (4):CD005530. PubMed ID: 22513932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine.
    Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; uberall M; Laussucq S; Eckhardt T; Meyer M; Engelhardt R; Christenson P
    Pediatrics; 1998 Jan; 101(1 Pt 1):1-11. PubMed ID: 9417143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    MMWR Recomm Rep; 1997 Mar; 46(RR-7):1-25. PubMed ID: 9091780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantity and Quality of Antibodies After Acellular Versus Whole-cell Pertussis Vaccines in Infants Born to Mothers Who Received Tetanus, Diphtheria, and Acellular Pertussis Vaccine During Pregnancy: A Randomized Trial.
    Wanlapakorn N; Maertens K; Vongpunsawad S; Puenpa J; Tran TMP; Hens N; Van Damme P; Thiriard A; Raze D; Locht C; Poovorawan Y; Leuridan E
    Clin Infect Dis; 2020 Jun; 71(1):72-80. PubMed ID: 31418814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children.
    Perez Chacon G; Ramsay J; Brennan-Jones CG; Estcourt MJ; Richmond P; Holt P; Snelling T
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013682. PubMed ID: 34693993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of infant and preschool pertussis vaccinations on memory B-cell responses in children at 4 years of age.
    Hendrikx LH; de Rond LG; Oztürk K; Veenhoven RH; Sanders EA; Berbers GA; Buisman AM
    Vaccine; 2011 Aug; 29(34):5725-30. PubMed ID: 21669247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of acellular pertussis vaccines: the Mainz study and other recent studies.
    Weigl JA; Bock HL; Clemens R; Zepp F; Habermehl P; Beutel K; Müschenborn S; Sümenicht G; Schuind A; von König CH; Neiss A; Laukamp S; Kiederle S; Schmitt HJ
    Ann Acad Med Singap; 1997 May; 26(3):320-5. PubMed ID: 9285026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.